CMR Parametric Mapping in Immune Checkpoint Inhibitor Myocarditis: Novel Noninvasive Tools in a Lethal Condition
- PMID: 33766257
- DOI: 10.1016/j.jacc.2021.01.043
CMR Parametric Mapping in Immune Checkpoint Inhibitor Myocarditis: Novel Noninvasive Tools in a Lethal Condition
Keywords: Lake Louise Criteria; T1 mapping; T2 mapping; cardiovascular magnetic resonance; immune checkpoint inhibitor; major adverse cardiovascular event; myocarditis.
Conflict of interest statement
Funding Support and Author Disclosures Dr. Kramer is a consultant for Bristol Myers Squibb on this topic. Dr. Hanson has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis.J Am Coll Cardiol. 2021 Mar 30;77(12):1503-1516. doi: 10.1016/j.jacc.2021.01.050. J Am Coll Cardiol. 2021. PMID: 33766256 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
